Expression of c-MET, low-molecular-weight cytokeratin, matrix metalloproteinases-1 and -2 in spinal chordoma
- PMID: 19302530
- DOI: 10.1111/j.1365-2559.2009.03278.x
Expression of c-MET, low-molecular-weight cytokeratin, matrix metalloproteinases-1 and -2 in spinal chordoma
Abstract
Aims: In skull base chordoma, c-MET expression has been reported to correlate with younger patient age and favourable prognosis; however, it also contributes to tumour invasiveness, especially in recurrent lesions, suggesting variable roles for c-MET according to clinical status. The aim of this study was to investigate the significance of c-MET expression in spinal chordoma, which affects patients who are 10-20 years older than those with skull base chordoma.
Methods and results: Using immunohistochemical techniques, the expression of c-MET and its ligand, hepatocyte growth factor (HGF) was investigated in 34 primary spinal chordomas and compared with other clinicopathological parameters. Expression of c-MET and HGF was observed in 85.3 and 21.7% of lesions, respectively. c-MET expression correlated with the expression of an epithelial marker, low-molecular-weight cytokeratin (CAM5.2). Lesions with higher c-MET expression showed significantly stronger expression of proteinases, including matrix metalloproteinase (MMP)-1 and MMP-2. However, c-MET expression was not associated with patient age, proliferative ability estimated by MIB-1 labelling index, or prognosis.
Conclusions: c-MET expression was observed in most spinal chordomas and correlated with the expression of CAM5.2, suggesting a relationship to an epithelial phenotype.
Comment in
-
Anti-Cytokeratin CAM5.2 (BD) does not act as a substitute of the CK8/18 monoclonal antibody. Comment on: 'Expression of c-MET, low-molecular-weight cytokeratin, matrix metalloproteinases-1 and -2 in spinal chordoma'. Histopathology 2009; 54; 607-613.Histopathology. 2010 May;56(6):810; author reply 810-1. doi: 10.1111/j.1365-2559.2010.03537.x. Histopathology. 2010. PMID: 20546346 No abstract available.
Similar articles
-
Expression of hepatocyte growth factor and c-MET in skull base chordoma.Cancer. 2008 Jan 1;112(1):104-10. doi: 10.1002/cncr.23141. Cancer. 2008. PMID: 17948912
-
Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma.Hum Pathol. 2008 Feb;39(2):217-23. doi: 10.1016/j.humpath.2007.06.005. Epub 2007 Oct 18. Hum Pathol. 2008. PMID: 17949787
-
Anti-Cytokeratin CAM5.2 (BD) does not act as a substitute of the CK8/18 monoclonal antibody. Comment on: 'Expression of c-MET, low-molecular-weight cytokeratin, matrix metalloproteinases-1 and -2 in spinal chordoma'. Histopathology 2009; 54; 607-613.Histopathology. 2010 May;56(6):810; author reply 810-1. doi: 10.1111/j.1365-2559.2010.03537.x. Histopathology. 2010. PMID: 20546346 No abstract available.
-
Phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor growth and prognosis in patients with bladder cancer: correlation with matrix metalloproteinase-2 and -7 and E-cadherin.Hum Pathol. 2009 Apr;40(4):496-504. doi: 10.1016/j.humpath.2008.09.011. Epub 2009 Jan 3. Hum Pathol. 2009. PMID: 19121849
-
Identifying mechanisms for therapeutic intervention in chordoma: c-Met oncoprotein.Spine (Phila Pa 1976). 2008 Dec 1;33(25):2774-80. doi: 10.1097/BRS.0b013e31817e2d1e. Spine (Phila Pa 1976). 2008. PMID: 19050584
Cited by
-
Leukemia Inhibitory Factor Promotes Aggressiveness of Chordoma.Oncol Res. 2017 Aug 7;25(7):1177-1188. doi: 10.3727/096504017X14874349473815. Epub 2017 Feb 28. Oncol Res. 2017. PMID: 28247842 Free PMC article.
-
MET overexpressing chordomas frequently exhibit polysomy of chromosome 7 but no MET activation through sarcoma-specific gene fusions.Tumour Biol. 2010 Jun;31(3):157-63. doi: 10.1007/s13277-010-0021-0. Epub 2010 Mar 6. Tumour Biol. 2010. PMID: 20512480
-
Systemic therapy options for unresectable and metastatic chordomas.Curr Oncol Rep. 2011 Aug;13(4):323-30. doi: 10.1007/s11912-011-0176-x. Curr Oncol Rep. 2011. PMID: 21584646 Review.
-
The Role of miRNAs 340-5p, 92a-3p, and 381-3p in Patients with Endometriosis: A Plasma and Mesenchymal Stem-Like Cell Study.Biomed Res Int. 2021 Sep 29;2021:5298006. doi: 10.1155/2021/5298006. eCollection 2021. Biomed Res Int. 2021. PMID: 34631883 Free PMC article.
-
Gain of chromosome 7 by chromogenic in situ hybridization (CISH) in chordomas is correlated to c-MET expression.J Neurooncol. 2011 Jan;101(2):199-206. doi: 10.1007/s11060-010-0250-5. Epub 2010 Jul 10. J Neurooncol. 2011. PMID: 20617367
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous